CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
Status:
Unknown status
Trial end date:
2011-12-01
Target enrollment:
Participant gender:
Summary
RATIONALE: CT-322 may stop the growth of glioblastoma multiforme by blocking blood flow to
the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the
growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving
CT-322 together with irinotecan may kill more tumor cells.
PURPOSE: This phase 2 trial is studying the side effects, tolerability, and efficacy of
CT-322 when given alone and in combination with irinotecan to patients with glioblastoma
multiforme.